Data on long-term survival of the NOD/Shi-scid IL-2Rγnull (NOG) mouse in two facilities

Yuji Yamashita; Tamio Sato; Kaori Noishiki; Kinji Kobayashi; Asako Uchiyama; Hiroyuki Izumi; Takashi Tamura; Masayuki Shikamura; Yu Oinishi; Miho Saito; Shin Kawamata

doi:10.2131/jts.46.453

Data on long-term survival of the NOD/Shi-scid IL-2Rγ^null (NOG) mouse in two facilities

J Toxicol Sci. 2021;46(10):453-469. doi: 10.2131/jts.46.453.

Authors

Affiliations

¹ Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Drug Safety Research Laboratories.
² Research & Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation at Kobe (FBRI).

PMID: 34602530
DOI: 10.2131/jts.46.453

Abstract

The objective of this study was to investigate an appropriate observation period for an evaluation of tumorigenicity in NOD/Shi-scid IL-2 Rγ^null (NOG) mice. At SNBL, 19 male and 19 female NOG mice were observed the general condition from 7 weeks old up to 68 weeks old and at FBRI, 7 male and 16 female NOG mice were observed the general condition throughout the lifespan from 7 weeks old. The survival rate started to decline rapidly around 54 to 56 weeks of age in both facilities without a facility difference. Based on these survival data, it seems reasonable to terminate a tumorigenicity study at 52 weeks of age.

Keywords: Histopathology; Human cell-based therapy products; NOG mice; Survival rate; Tumorigenicity.

MeSH terms

Animals
Female
Male
Mice
Mice, Inbred NOD*
Mice, SCID